RT Journal Article
SR Electronic
T1 Neurofeedback-enabled beta power control with a fully implanted DBS system in patients with Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.22.23290293
DO 10.1101/2023.05.22.23290293
A1 Rohr-Fukuma, Manabu
A1 Stieglitz, Lennart H.
A1 Bujan, Bartosz
A1 Jedrysiak, Piotr
A1 Oertel, Markus F.
A1 Salzmann, Lena
A1 Baumann, Christian R.
A1 Imbach, Lukas L.
A1 Gassert, Roger
A1 Bichsel, Oliver
YR 2023
UL http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290293.abstract
AB Parkinsonian motor symptoms are linked to pathologically increased beta oscillations in the basal ganglia. Studies with externalised deep brain stimulation electrodes showed that Parkinson patients were able to rapidly gain control over these pathological basal ganglia signals through neurofeedback. Studies with fully implanted deep brain stimulation systems duplicating these promising results are required to grant transferability to daily application. In this study, seven patients with idiopathic Parkinson’s disease and one with familial Parkinson’s disease were included. In a postoperative setting, beta oscillations from the subthalamic nucleus were recorded with a fully implanted deep brain stimulation system and converted to a real-time visual feedback signal. Participants were instructed to perform bidirectional neurofeedback tasks with the aim to modulate these oscillations. While receiving regular medication and deep brain stimulation, participants were able to significantly improve their neurofeedback ability and achieved a significant decrease of subthalamic beta power (median reduction of 31% in the final neurofeedback block). We could demonstrate that a fully implanted deep brain stimulation system can provide visual neurofeedback enabling patients with Parkinson’s disease to rapidly control pathological subthalamic beta oscillations.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05101161Funding StatementFunding for the conduction of this study was provided by the Dr. Wilhelm Hurka Stiftung.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Canton of Zurich (Kantonale Ethikkommision Zuerich) gave ethical approval for this work under the BASEC number 2021-00352.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe encrypted data can be made available upon reasonable request.